Adco-Dol

For the treatment of mild to moderate pain. Suitable for migraine, headache, rheumatic pain, period pain, toothache, neuralgia, sore throats and feverishness and the symptomatic relief of colds and influenza.

Hypersensitivity to paracetamol, Caffeine (Adco-Dol), Codeine (Adco-Dol) or any of the other constituents. Conditions where morphine and opioids are contraindicated, eg acute asthma, respiratory depression, acute alcoholism, head injuries, raised intra-cranial pressure and following biliary tract surgery.

The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine.

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding. Occasional doses have no significant effect.

The use of drugs which induce hepatic microsomal enzymes, such as anticonvulsants and oral contraceptive steroids, may increase the extent of metabolism of paracetamol, resulting in reduced plasma concentrations of the drug and a faster elimination rate.

Drugs which induce hepatic microsomal enzymes, such as alcohol and barbiturates, may increase the hepatotoxicity of paracetamol, particularly after overdose.

CNS depression or excitation may occur if Codeine (Adco-Dol) is given to patients receiving monoamine oxidase inhibitors, or within two weeks of stopping treatment with them. The effects of CNS depressants (including alcohol) may be potentiated by Codeine (Adco-Dol).

Concurrent use of Codeine (Adco-Dol) with antidiarrhoeal and antiperistaltic agents may increase the risk of severe constipation. Concomitant use of antimuscarinics or medications with antimuscarinic action may result in an increased risk of severe constipation, which may lead to paralytic ileus and/or urinary retention.

Quinidine can inhibit the analgesic effect of Codeine (Adco-Dol).

Codeine (Adco-Dol) may delay the absorption of mexiletine and thus reduce the antiarrhythmic effect of the latter. Codeine (Adco-Dol) may antagonise the gastrointestinal effects of metoclopramide and domperidone. Cimetidine inhibits the metabolism of opioid analgesics resulting in increased plasma concentrations.

Naltrexone blocks the therapeutic effect of opioids.

"The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine.

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding. Occasional doses have no significant effect.

The use of drugs which induce hepatic microsomal enzymes, such as anticonvulsants and oral contraceptive steroids, may increase the extent of metabolism of paracetamol, resulting in reduced plasma concentrations of the drug and a faster elimination rate.

Drugs which induce hepatic microsomal enzymes, such as alcohol and barbiturates, may increase the hepatotoxicity of paracetamol, particularly after overdose.

CNS depression or excitation may occur if Codeine (Adco-Dol) is given to patients receiving monoamine oxidase inhibitors, or within two weeks of stopping treatment with them. The effects of CNS depressants (including alcohol) may be potentiated by Codeine (Adco-Dol).

Concurrent use of Codeine (Adco-Dol) with antidiarrhoeal and antiperistaltic agents may increase the risk of severe constipation. Concomitant use of antimuscarinics or medications with antimuscarinic action may result in an increased risk of severe constipation, which may lead to paralytic ileus and/or urinary retention.

Quinidine can inhibit the analgesic effect of Codeine (Adco-Dol).

Codeine (Adco-Dol) may delay the absorption of mexiletine and thus reduce the antiarrhythmic effect of the latter. Codeine (Adco-Dol) may antagonise the gastrointestinal effects of metoclopramide and domperidone. Cimetidine inhibits the metabolism of opioid analgesics resulting in increased plasma concentrations.

Naltrexone blocks the therapeutic effect of opioids.

"